Basal cell carcinoma: what new can be learned about the most common human cancer? A cross-sectional prospective study of 180 cases in a single centre

Basal cell carcinoma (BCC) is the most common human cancer worldwide, and is a subtype of nonmelanoma skin cancer, characterized by a constantly increasing incidence due to an aging population and widespread sun exposure. Although the mortality from BCC is negligible, this tumor can be associated with significant morbidity and cost. This review presents a literature overview of BCC from pathophysiology to novel therapeutic approaches. Several histopathological BCC subtypes with different prognostic values have been described. Dermoscopy and, more recently, reflectance confocal microscopy have largely improved BCC diagnosis. Although surgery is the first-line treatment for localized BCC, other nonsurgical local treatment options are available. BCC pathogenesis depends on the interaction between environmental and genetic characteristics of the patient. Specifically, an aberrant activation of Hedgehog signaling pathway is implicated in its pathogenesis. Notably, Hedgehog signaling inhibitors, such as vismodegib and sonidegib, are successfully used as targeted treatment for advanced or metastatic BCC. Furthermore, the implementation of prevention measures has demonstrated to be useful in the patient management.

Download Full-text

Molecular detection of Merkel cell polyomavirus in basal cell carcinoma and perilesional tissue: a cross-sectional study

Anais Brasileiros de Dermatologia ◽

10.1016/j.abd.2019.10.007 ◽

2020 ◽

Vol 95 (4) ◽

pp. 527-528

Author(s):

Marianna Tavares Venceslau Gonçalves ◽

Rafael Brandão Varella ◽

Núbia Karla de Oliveira Almeida ◽

Maria Angelica Arpon Marandino Guimarães ◽

Flávio Barbosa Luz

Keyword(s):

Basal Cell Carcinoma ◽

Cell Carcinoma ◽

Basal Cell ◽

Molecular Detection ◽

Cross Sectional Study ◽

Merkel Cell Polyomavirus ◽

Merkel Cell ◽

Sectional Study ◽

Cross Sectional

Download Full-text

Excision of Head and Neck Basal Cell Carcinoma With a Rapid, Cross-sectional, Frozen-Section Technique

Archives of Facial Plastic Surgery ◽

10.1001/archfaci.4.2.114 ◽

2002 ◽

Vol 4 (2) ◽

pp. 114-119 ◽

Cited By ~ 29

Author(s):

Stuart H. Bentkover ◽

Donald M. Grande ◽

Henry Soto ◽

Beth A. Kozlicak ◽

Donna Guillaume ◽

...

Keyword(s):

Basal Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Basal Cell ◽

Frozen Section ◽

Cross Sectional ◽

Section Technique

Download Full-text

Micrographic surgery (fresh-tissue Tübingen technique) for treatment of basal cell carcinoma of the head: A single-centre report

The Journal of Dermatology ◽

10.1111/j.1346-8138.2008.00546.x ◽

2008 ◽

Vol 35 (10) ◽

pp. 678-679 ◽

Cited By ~ 1

Author(s):

Roberto CECCHI ◽

Mario PAVESI ◽

Laura BARTOLI ◽

Luigi BRUNETTI ◽

Valentina RAPICANO ◽

...

Keyword(s):

Basal Cell Carcinoma ◽

Cell Carcinoma ◽

Basal Cell ◽

Micrographic Surgery ◽

Single Centre ◽

Fresh Tissue

Download Full-text

Photodynamic Therapy for Basal Cell Carcinoma: The Clinical Context for Future Research Priorities

Molecules ◽

10.3390/molecules25225398 ◽

2020 ◽

Vol 25 (22) ◽

pp. 5398

Author(s):

Nicholas J. Collier ◽

Lesley E. Rhodes

Keyword(s):

Photodynamic Therapy ◽

Basal Cell Carcinoma ◽

Cell Carcinoma ◽

Basal Cell ◽

Human Cancer ◽

Research Priorities ◽

Future Research ◽

Clinical Context ◽

Light Delivery ◽

Established Treatment

Photodynamic therapy (PDT) is an established treatment option for low-risk basal cell carcinoma (BCC). BCC is the most common human cancer and also a convenient cancer in which to study PDT treatment. This review clarifies challenges to researchers evident from the clinical use of PDT in BCC treatment. It outlines the context of PDT and how PDT treatments for BCC have been developed hitherto. The sections examine the development of systemic and subsequently topical photosensitizers, light delivery regimens, and the use of PDT in different patient populations and subtypes of BCC. The outcomes of topical PDT are discussed in comparison with alternative treatments, and topical PDT applications in combination and adjuvant therapy are considered. The intention is to summarize the clinical relevance and expose areas of research need in the BCC context, ultimately to facilitate improvements in PDT treatment.

Download Full-text

DDX5 Silencing Suppresses the Migration of Basal cell Carcinoma Cells by Downregulating JAK2/STAT3 Pathway

Technology in Cancer Research & Treatment ◽

10.1177/1533033819892258 ◽

2019 ◽

Vol 18 ◽

pp. 153303381989225 ◽

Cited By ~ 2

Author(s):

Zhe Quan ◽

Bei-bei Zhang ◽

Fang Yin ◽

Jiru Du ◽

Yuan-ting Zhi ◽

...

Keyword(s):

Basal Cell Carcinoma ◽

Cell Carcinoma ◽

Basal Cell ◽

Hedgehog Signaling ◽

Human Cancer ◽

Carcinoma Cells ◽

Terminal Deoxynucleotidyl Transferase ◽

Migration And Invasion ◽

Stat3 Pathway

Basal cell carcinoma is driven by the aberrant activation of hedgehog signaling. DEAD (Asp-Glu-Ala-Asp) box protein 5 is frequently overexpressed in human cancer cells and associated with the tumor growth and invasion. The purpose of this study was to investigate the role of DEAD (Asp-Glu-Ala-Asp) box protein 5 in the growth, migration, and invasion of basal cell carcinoma. The role of DEAD (Asp-Glu-Ala-Asp) box protein 5 was detected by quantitative real-time polymerase chain reaction, Western blot, and terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling assay in basal cell carcinoma cells. The associations between JAK2/STAT3 pathway and DEAD (Asp-Glu-Ala-Asp) box protein 5 were analyzed in basal cell carcinoma cells. Results showed that DEAD (Asp-Glu-Ala-Asp) box protein 5 is overexpressed in basal cell carcinoma cells. DEAD (Asp-Glu-Ala-Asp) box protein 5 knockdown inhibited the migration and invasion of basal cell carcinoma cells. DEAD (Asp-Glu-Ala-Asp) box protein 5 knockdown increased the apoptosis of basal cell carcinoma cells induced by tunicamycin. Results found that DEAD (Asp-Glu-Ala-Asp) box protein 5 knockdown increased JAK2 and STAT3 expression in basal cell carcinoma cells. JAK2 inhibitor decreased STAT3 expression and abolished the inhibitory effects of DEAD (Asp-Glu-Ala-Asp) box protein 5 silencing on migration and invasion in basal cell carcinoma cells. In conclusion, these results indicate that DEAD (Asp-Glu-Ala-Asp) box protein 5 is a potential target for inhibiting basal cell carcinoma cells growth, migration, and invasion by downregulating JAK2/STAT3 pathway.

Download Full-text

Comparison of BCL-2 Ecpression in Periocular Basal Cell Carcinoma Aggressive and Non-Aggressive Types in Mohammad Hoesin Hospital Palembang

Sriwijaya Journal of Ophthalmology ◽

10.37275/sjo.v1i2.40 ◽

2018 ◽

Vol 1 (2) ◽

pp. 18-36

Author(s):

Fera Yunita Rodhiaty ◽

Ika Kartika ◽

Ibrahim

Keyword(s):

Basal Cell Carcinoma ◽

Cell Carcinoma ◽

Basal Cell ◽

Malignant Tumor ◽

Histopathological Examination ◽

Basal Layer ◽

Growth Patterns ◽

Bivariate Analysis ◽

Fisher Exact Test ◽

Cross Sectional

Abstract Background: Basal cell carcinoma (BCC) is a malignant tumor originating from non- keratinizing cells originating from the basal layer of the epidermis. Basal cell carcinoma is the most common malignant tumor, nearly 90% of all non-melanoma skin cancers. Clinically, BCC is difficult to distinguish, final diagnosis determined based on histopathological examination of complete tumor tissue. Based on histological growth patterns, BCC is divided into two, non- aggressive type (nodular and superficial) and aggressive type (infiltration, micronodular, fibroepithelial, basoskuamosa, keratotic, adnexal differentiation). The examination technique by analyzing the proteins or genes involved is related to the aggressiveness of basal cell carcinoma. Objective: This study was conducted to determine the comparison of expression of Bcl-2 in periocular basal type aggressive and non-aggressive carcinomas in dr. Mohammad Hoesin Palembang. Methodology: A cross sectional analytic study from 26 periocular basal cell carcinoma patients in RSUP dr. Mohammad Hoesin Palembang, January 2014- June 2018. Histopathologic features were examined with hematoxylin-eosine staining and imunohistochemical were examined with Bcl-2 monoclonal antibody. Data were analyzed by bivariate analysis, using chi-square test and fisher exact test. Results: Positive Bcl-2 expression was more common in periocular basal cell carcinoma (93.8%) than aggressive (50%), and nodular type (93.8%) compared to other types of histological differentiation. Positive Bcl-2 expression was also higher in female patients (90.9%) than males (66.7%). There is a significant relationship between expression of Bcl-2 and growth patterns, differentiation of cell histology and also sex of patients with basal cell carcinoma. Conclusion: In this study, there was a significant correlation between expression of Bcl-2 and aggressive and non-aggressive periocular basal cell carcinoma in RSUP dr. Mohammad Hoesin Palembang.

Download Full-text